Efficacy and safety of Ginkgo biloba leaf extract injection for vascular cognitive impairment: a systematic review and meta-analysis.

Authors

Jingchao Miao, Yaoyuan Liu, Huichuan Feng, Shujie Zan, Changhong Miao, Jiabao Wang, Xinyao Jin, Fengwen Yang, Wentai Pang

Published in

Frontiers in pharmacology. Volume 17. Pages 1720444. Epub Apr 13, 2026.

Abstract

Shuxuening injection (SXNI), a standardized injectable formulation of Ginkgo biloba leaf extract, is widely used in China for vascular cognitive impairment (VCI), However, evidence-based evaluation remains limited.
Randomized controlled trials published before 1 September 2025, were searched in eight databases. Patients had vascular cognitive impairment (VCI), with the control group receiving conventional treatment and the treatment group receiving additional SXNI therapy. The primary outcome was the Mini-Mental State Examination (MMSE), while secondary outcomes included the Hasegawa Dementia Scale (HDS), Barthel Index (BI), overall response rate, National Institutes of Health Stroke Scale (NIHSS), and adverse event incidence. Risk of bias was assessed using the revised Cochrane Risk of Bias tool. Risk ratios (RR) were used for binary variables; mean differences (MD) with 95% confidence intervals (CI) were used for continuous variables.
Twenty-two trials (n = 2,375) were included. All trials were conducted in China between 2005 and 2025. Compared with the control group, SXNI was associated with higher MMSE (MD 3.61, 95% CI 3.06-4.17), HDS (MD 1.30, 95% CI 0.21-2.39), and BI (MD 9.06, 95% CI 4.66-13.45), a higher overall response rate (RR 1.27, 95% CI 1.21-1.33), and lower NIHSS (MD -6.17, 95% CI -7.90 to -4.45). Seven studies reported adverse events; and there was no significant difference in the incidence of adverse events (RR 0.72, 95% CI 0.36-1.44).
The addition of SXNI to conventional treatment may provide additional benefits in cognition, neurological function, and activities of daily living with no significant increase in reported adverse events compared with conventional treatment. However, the certainty of evidence is limited by methodological weaknesses and uncertainty regarding the comparability of preparations from different manufacturers. Therefore, high-quality studies are needed to confirm these findings.
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=557472, identifier CRD42024557472.

PMID:
42051256
Bibliographic data and abstract were imported from PubMed on 14 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.